After a year and a half of deliberations, a deal has been reached on a highly charged effort to expand who around the world has the right to circumvent intellectual property rules to manufacture, import and export lifesaving COVID-19 vaccines. The deal came out of some nail biting, late night negotiations this week in Geneva, at the World Trade Organization’s big ministerial meeting, the first to be in-person since 2017. But as The World’s Elana Gordon reports, both drug companies and global health advocates are disappointed with the result.